An excellent read on contemporary benchmark outcomes with radical cystectomy for #bladdercancer by Anirban Mitra Sia Daneshmand, M.D. Noteworthy: stable RFS but improved OS ; increased use of NAC; nodal yield 'secrets' of USC Urology ; short stay with ERAS; large % open vs robotic

Update to the classic Stein paper that often is helpful during patient counseling.. good for trainees know both of these University of Iowa Urology Andrew Vitale Courtney Yong MD

A must read paper: The hallmarks of cancer updated concept because #cancer is really complex! Cancer Discovery cancerdiscovery.aacrjournals.org/content/12/1/31 OncoAlert AACR Dana-Farber Lank Center for Genitourinary Oncology cancerdiscovery.aacrjournals.org/content/12/1/31

🎯 ICYMI February issue of Journal of Urology highlights evolution of USC Urology experience in surgical management and outcomes of patients undergoing radical cystectomy for #BladderCancer. Also part of Amer. Urol. Assn. home study course for CME credits❗️ auajournals.org/doi/10.1097/JU…

Thanks to OncLive.com for highlighting our findings from the Phase 3 Nadofaragene firadenovec trial on the potentially synergistic role for immune checkpoint inhibition in select BCG-unresponsive NMIBC patients. See details in #AUA22 MP54-05 tomorrow Amer. Urol. Assn. MD Anderson Cancer Center

Findings from our Dr. Anirban Mitra fuel the hypothesis that pembrolizumab plus nadofaragene firadenovec could benefit patients with high-grade, Bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer. Read more: bit.ly/3wujVfT #AUA22 #EndCancer

Coverage of our hypothesis-generating results presented at #AUA22 by OncLive.com in select patients with BCG-unresponsive non-muscle-invasive #bladdercancer Amer. Urol. Assn. MD Anderson Cancer Center

Evaluating intravesical nadofaragene firadenovec and immune checkpoint blockade combination therapy in BCG-unresponsive #NMIBC: Evidence from a phase 3 trial. Presented by Anirban Mitra MD Anderson Cancer Center. #AUA22 written coverage by @rksayyid > bit.ly/3yRiryW

Nadofaragene firadenovec combined w/ immune checkpoint inhibitors may play a synergistic role in the treatment of patients with Bacillus Calmette–Guérin-unresponsive non–muscle invasive bladder cancer. Anirban Mitra MD Anderson Cancer Center #blcsm #oncology ow.ly/L4op50JGVuh

Extremely grateful for the awesome experience and mentorship during my Society of Urologic Oncology fellowship MD Anderson Cancer Center. Learned several new tricks, broadened my horizons and made new friends along the way. 🙏🏽

Appreciate the stimulating discussion with Ashish M. Kamat, MD, MBBS UroToday.com on the contemporary USC Urology radical cystectomy experience for #bladdercancer Journal of Urology Amer. Urol. Assn. 🙏🏽 auajournals.org/doi/10.1097/JU… Sia Daneshmand, M.D. Dr. Hooman Djaladat Anne Schuckman Sumeet Bhanvadia

📢 Calling all investigators interested in #bladdercancer. See link below. journals.sagepub.com/page/tau/call-… Therapeutic Advances in Urology Rebecca Johnson UroSoMe

Congratulations Donna Hansel MD, PhD!

Talking about #BladderCancer for #UrologyWeek this year... Have we mentioned we have a special collection on the topic? Guest Edited by Anirban Mitra, the collection is an evidence based look into the management of bladder cancer. Check it out! 📑 bit.ly/3Rmggcu #FOAMed

The MD Anderson Cancer Center Society of Urologic Oncology fellowship is ramping up for another year of applicant interviews Watch for an open house in November Contact me to set up an introduction at the Society of Urologic Oncology meeting in December or ASCO in Feb Interview dates TBD (March/April 2022) #oncsurgery

➡️Largest series of Rob PC-RPLND: 90 pts, 7 centers. 🎯#Robotic PC-RPLND is safe with effective short-term #cancer control in well-selected pts at centers with expertise in #testicularcancer and MIS. Dr. Hooman Djaladat USC Urology Society of Urologic Oncology 🔗authors.elsevier.com/c/1g8V13r93nVE…

Amazing. IFN-alpha gene therapy is effective and FDA approved in bladder cancer. Thanks Brian F. Chapin for spreading the news. Product of decades of research led by Colin Dinney. fda.gov/news-events/pr…

SYSTEMATIC REVIEW 👉Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic Review of Commercially Available Assays 👈 by John R. Heard, MD, MS Anirban Mitra Cedars-Sinai Cancer at Cedars-Sinai Cedars-Sinai Academic Medicine content.iospress.com/articles/bladd… Dr. Bishoy M. Faltas Dan Theodorescu splernerMD

⚠️For PhDs who are thinking about jumping ship and diving into industry: Industry isn't necessarily better than academia. I have straddled both worlds. Here are 5 MYTHS about academia vs. industry:

Delighted to share our new paper on rob PC-RPLND 🏥11 centers > 173 pts 🤖4% conversion rate: higher after salvage chemo and mass>5cm 🩸EBL 100, LOS 2d ➡️median FU 22mo: 8 recur (3 in-field) ↗️4yr RFS 93% Dr. Hooman Djaladat Eur Urol Focus USC Urology 🔗authors.elsevier.com/c/1k6ci8Yy0LUa…